Ã¢â?¬Å?DOUBLE BLIND RANDOMIZED PLACEBO CONTROLLED MULTICENTRIC CLINICAL TRIAL OF AYUSH M-3 IN THE MANAGEMENT OF MIGRAINE - AYUSH M-3 in Migraine

CCRAS0 个研究点目标入组 0 人开始时间: 待定最近更新: 2022年10月17日

试验速览

暂无简介。

•1.Patients of either sex aged in between 18 to 60 years.
•2. Diagnosed cases of Migraine with or without aura as per International Headache
•Society-ICHD-III (International classification of Headache Disorders 3rdversion).
•3.Patients with up to Grade III severity as per MIDAS scale.
•4.Willing to participate in the study

•1. Patients who were suffering from headache due to space occupying lesions and other secondary reasons.
•2.Patients with concurrent serious cardiac, Hepatic Dysfunction (defined as AST and/or ALT > 2 times of the upper normal limit) or Renal Dysfunction (defined as S. creatinine > 1.2mg/dl), uncontrolled Pulmonary Dysfunction (Asthmatic and COPD patients) or other concurrent severe disease.
•3.Patients with evidence of malignancy
•4.Known cases of psychosis, depression, schizophrenia and other psychiatric illness etc.
•5.Patients on Ã?Â² blockers and Calcium channel blockers and or on prophylactic medicine for migraine.
•6.Patients with uncontrolled Hypertension (BP >160/100 mm of Hg)
•7.Patients with uncontrolled Diabetes mellitus {HbA1c > 8%).
•8.Patients suffering from any major systemic illness necessitating long term drug treatment.
•9.Pregnant women or planning to conceive or lactating woman.
•10. Any other condition which the Principal Investigator thinks may jeopardize the study

发起方

CCRAS